The Aenova Group, a global contract manufacturer and development service provider for the pharmaceutical and healthcare industry, and Galvita, a Swiss start-up company specializing in the development of patient-friendly, age-appropriate dosage forms, have entered into a partnership to improve the development, formulation, and production of oral dosage forms. To this end, Galvita brings knowledge of specific child- and senior-friendly formulations that feature faster oral disintegration, better taste masking and higher drug loading than oral dosage forms currently available on the market.
Cytotoxics and cytostatics are in increased demand in the global pharmaceutical market. To meet this steadily increasing demand, Aenova, a leading development service provider and contract manufacturer for the pharmaceutical and healthcare industries, has built a new building at its Regensburg site for the development and production of highly effective active pharmaceutical ingredients (APIs). The total investment of around €25 million will enable the company to expand its production of highly potent active ingredients up to OEB 5 and, in particular, of cancer drugs. The new building was opened on June 22, 2023.
Aenova with new organizational structure supporting future strategy
Career orientation fair in Regensburg
Efficient handling of high-potent APIs, a CDMO perspective (lecture at 8th Annual High Potent Medicines Conference Milan 2023)
Successful recertifications at Aenova site Sisseln
Peter Waller appointed as new CFO of Aenova
Enabling innovation: challenges and strategies in solid dosage forms drug development services (lecture at World Pharma Summit 2023)
CEO Jan Kengelbach about Trends in CDMO Market (Interview in GBR Life Sciences Report 2023)